Andere Kunden interessierten sich auch für
![Non-small Cell Lung Cancer]( "Non-small Cell Lung Cancer")
Non-small Cell Lung Cancer88,99 €![A Popular and Impartial Estimate of the Present Value of Vaccination, As a Security Against Small Pox]( "A Popular and Impartial Estimate of the Present Value of Vaccination, As a Security Against Small Pox")
A Popular and Impartial Estimate of the Present Value of Vaccination, As a Security Against Small Pox34,99 €![Treatments for Squamous Cell Cancer]( "Treatments for Squamous Cell Cancer")
Treatments for Squamous Cell Cancer67,99 €![Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer]( "Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer")
Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer83,99 €![Half a Century of Small-pox and Vaccination; Being the Milroy Lectures Delivered Before the Royal College of Physicians of London on March 13th, 18th and 20th, 1919]( "Half a Century of Small-pox and Vaccination; Being the Milroy Lectures Delivered Before the Royal College of Physicians of London on March 13th, 18th and 20th, 1919")
Half a Century of Small-pox and Vaccination; Being the Milroy Lectures Delivered Before the Royal College of Physicians of London on March 13th, 18th and 20th, 191932,99 €![Training Schools for Nurses in Small Cities]( "Training Schools for Nurses in Small Cities")
Training Schools for Nurses in Small Cities33,99 €![The Diagnosis of Small Pox]( "The Diagnosis of Small Pox")
The Diagnosis of Small Pox44,99 €
Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody-drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.